it happens quite often @Yor and @otherperspective. Put your cash in to see more of the IP of the molecule in development and so you can have first dibs at a directors seat (for more capital of course) without risking your own share price Many small biotechs have Big Pharma sitting on the register with 15% of the company and a seat at the table. How fortunate are we to get such approval from Novartis
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-674
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |